Page 38 - RPIA_25-3

Luís Taborda Barata

9. Goldstein G, Norman DJ, Shield III CF, et al. OKT3 monoclonal 14. http://www.who.int/medicines/services/inn/BioRev2013.pdf. Página
antibody reversal of acute renal allograft rejection unresponsive web da World Health Organization. Consultada a 22 de março
to conventional immunosuppressive treatments. Prog Clin Biol de 2017.
Res 1986; 224: 239 -49. 15. Boyman O, Kaegi C, Akdis M, et al. EAACI IG biologicals task
10. Köhler G, Milstein C. Continuous cultures of fused cells secreting force paper on the use of biologic agents in allergic disorders.
antibody of predefined specificity. Nature 1975; 256: 495 -7. Allergy 2015; 70: 727 -54.
11. Li F, Vijayasankaran N, Shen AY, Kiss R, Amanullah A. Cell culture 16. Fernandes R. Medicamentos biológicos e biossimilares em Por-
processes for monoclonal antibody production. mAbs 2010; 2: 466 -77. tugal: caracterização do mercado, do consumo e da segurança.
12. Rodgers KR, Chou RC. Therapeutic monoclonal antibodies and Dissertação de mestrado apresentada na Faculdade de Farmácia
derivaties: historical perspectives and future directions. Biotech- da Universidade de Lisboa. 2015. Disponível em http://repositorio.
nol Adv 2016; 34: 1149 -58. ul.pt/handle/10451/25000.
13. McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage anti- 17. Revets H, de Baetselier P, Muyldermans S. Nanobodies as novel
bodies: filamentous phage displaying antibody variable domains. agents for cancer therapy. Exp Opin Biol Ther 2005; 5: 111 -24.
Nature 1990; 348: 552 -4.

164

REVIST A POR TUGUESA DE IMUNO ALERGOLOGIA